Acylating drugs: redesigning natural covalent inhibitors

Current Opinion in Chemical Biology

Volumn 14, Issue 3, 2010, Pages 421-427

  Kluge, Arthur F ^a   Petter, Russell C ^a  

^a Avila Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; BETA LACTAM ANTIBIOTIC; BETA LACTAM DERIVATIVE; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BLI 489; CEFTAZIDIME; CLAVULANIC ACID; EZETIMIBE; FATTY ACID SYNTHASE; LACTACYSTIN; LACTACYSTIN BETA LACTONE; LACTIVICIN; NXL 104; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 2A; POLYKETIDE; SALINOSPORAMIDE A; SULBACTAM; TAZOBACTAM; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ACYLATION; COVALENT BOND; DEACYLATION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME MECHANISM; GROWTH INHIBITION; HUMAN; HYDROLYSIS; NONHUMAN; PROTEIN TRANSPORT; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR GROWTH;

ACYLATION; ANIMALS; BETA-LACTAMASES; BETA-LACTAMS; DRUG DISCOVERY; HUMANS; LACTONES; PENICILLIN-BINDING PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS);

EID: 77952542136     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2010.03.035     Document Type: Review

References (50)

1. Robertson J.G. Mechanistic basis of enzyme-targeted drugs. Biochemistry 44 (2005) 5561-5571
2. Potashman M.H., and Duggan M.E. Covalent modifiers: an orthogonal approach to drug design. J Med Chem 52 (2009) 1231-1246. A comprehensive Perspective article that details the mechanisms employed by drugs that covalently modify their targets. This article makes the important point that covalently modifying drugs can be both safe and effective.
3. Drahl C., Cravatt B.E., and Sorenson E.J. Protein-reactive natural products. Angew Chem Int Ed 44 (2005) 5788-5809
4. Goffin C., and Ghusyen J.-M. Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol Mol Biol Rev 62 (1998) 1079-1093
5. Silver L. Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6 (2007) 41-55. An analysis of how antibacterial efficacy, spectrum, potency, and low potential for resistance are crucially linked to covalently modifying multiple PBPs.
6. Wolfe S., Jin H., Yang K., Kim C.-K., and McEachern E. Interactive design and synthesis of a novel antibacterial agent. Can J Chem 72 (1994) 1051-1065
7. Talbot M.K., Schaefer F., Brocks V., and Christenson J.G. Reactivation of peptidoglycan synthesis in ether-permeabilized Escherichia coli after inhibition by β-lactam antibiotics. Antimicrob Agents Chemother 33 (1989) 2101-2108
8. Chambers H.F., Sachdeva M.J., and Hackbarth C.J. Kinetics of penicillin binding to penicillin-binding proteins of Staphylococcus aureus. Biochem J 301 (1994) 139-144
9. Lu Y.-P., Kincade E., Sun Y., and Bauer M.D. Kinetics of β-lactam interactions with penicillin-susceptible and -resistant penicillin-binding protein 2x proteins from Streptococcus pneumonia. J Biol Chem 276 (2001) 31494-31501
10. Silvaggi N.R., Josephine H.R., Kuzin A.P., Nagarajan R., Pratt R.F., and Kelly J.A. Crystal structures of complexes between the R61 DD-peptidase and peptidoglycan-mimetic beta-lactams: a non-covalent complex with a "perfect penicillin". J Mol Biol 345 (2005) 521-533
11. Kumar I., Josephine H.R., and Pratt R.F. Reactions of peptidoglycan-mimetic beta-lactams with penicillin-binding proteins in vivo and in membranes. ACS Chem Biol 2 (2007) 620-624. Shows that β-lactams with peptidoglycan-mimetic side chains are not more reactive than 'drug-like' analogs and makes the important point that substrate recognition involves an extended structure.
12. Yamada M., Watanabe T., Miyara T., Baba N., Saito J., Takeuchi Y., and Ohsawa F. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother 51 (2007) 3902-3907
13. Kuzin A.P., Liu H., Kelly J.A., and Knox J.R. Binding of cephalothin and cefotaxime to D-Ala-D-Ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum beta-lactamases. Biochemistry 34 (1995) 9532-9540
14. Lee W., McDonough M.A., Kotra L., Li Z.H., Silvaggi N.R., Takeda Y., Kelly J.A., and Mobashery S. A 1.2-Å snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A 98 (2001) 1319-1320
15. Nicholas R.A., Krings S., Tomberg J., Nicola G., and Davies C. Crystal structure of wild-type penicillin-binding protein 5 from Escherichia coli: implications for deacylation of the acyl-enzyme complex. J Biol Chem 278 (2003) 52826-52833
16. Fuda C., Hesek D., Lee M., Heilmayer W., Novak R., Vakulenko S.B., and Mobashery S. Mechanistic basis for the action of new cephalosporin antibiotics effective against methicillin- and vancomycin-resistant Staphylococcus aureus. J Biol Chem 281 (2006) 10035-10041
17. Macheboeuf P., Fischer D.S., Brown Jr. T., Zervosen A., Luxen A., Joris B., Dessen A., and Schofield C.J. Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins. Nat Chem Biol 3 (2007) 565-569
18. Bulychev A., and Mobashery S. Class C, β-lactamases operate at the diffusion limit for turnover of their preferred cephalosporin substrates. Antimicrob Agents Chemother 43 (1999) 1743-1746
19. Mansour T.S., Bradford P.A., and Venkatesan A.M. Recent developments in β-lactamases and inhibitors. Ann Rep Med Chem 43 (2008) 247-267. A survey of general principles and recent lead structures.
20. Nukaga M., Bethel C.R., Thompson J.M., Hujer A.M., Anderson V.E., Knox J.R., and Bonomo R.A. Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. J Am Chem Soc 130 (2008) 12656-12662. A case study for the use of structural biology to understand the principles of β-lactamase inhibition.
21. Bulychev A., Massova I., Miyashita K., and Mobashery S. Nuances of mechanisms and their implications for evolution of the versatile β-lactamase activity: from biosynthetic enzymes to drug resistance factors. J Am Chem Soc 119 (1997) 7619-7625
22. Sandanayaka V., and Prashad A.S. Resistance to β-lactam antibiotics: structure and mechanism based design of β-lactamase inhibitors. Curr Med Chem 9 (2002) 1145-1165
23. Nukaga M., Abe T., Venkatesan A.M., Mansour T.S., Bonomo R.A., and Knox J.R. Inhibition of Class A and Class C β-lactamases by penems: crystallographic structures of a NOVEL 1,4-thiazepine intermediate. Biochemistry 42 (2003) 13152-13159
24. Stachyra T., Levasseur P., Pechereau M.-C., Girard A.-M., Claudon M., Miossec C., and Black M.T. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenamases. J Antimicrob Chemother 64 (2009) 326-329. In late 2009 AstraZeneca announced a deal to acquire Novexel, the originator of NXL104, and to develop this β-lactamase inhibitor in two drug combinations for treating drug-resistant infections.
25. Padayatti P.S., Helfand M.S., Totir M.A., Carey M.P., Hujer A.M., Carey P.R., Bonomo R.A., and van den Akker F. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 Å crystal structure. Biochemistry 43 (2004) 843-8488
26. Sun T., Bethel C.R., Bonomo R.A., and Knox J.R. Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant. Biochemistry 43 (2004) 14111-14117
27. Kuzin A.P., Nukaga Y., Hujer A., Bonomo R.A., and Knox J.R. Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam. Biochemistry 40 (2001) 1861-1866
28. Helfand M.S., Totir M.A., Carey M.P., Hujer A.M., Bonomo R.A., and Carey P.R. Following the reactions of mechanism-based inhibitors with β-lactamase by Raman crystallography. Biochemistry 42 (2003) 13386-13392
29. Veinberg G., Vorona M., Shestakova I., Kanepe I., and Lukevics E. Design of β-lactams with mechanism-based non-antibacterial activities. Curr Med Chem 10 (2003) 1741-1757
30. Burnett D.A. β-Lactam cholesterol absorption inhibitors. Curr Med Chem 11 (2004) 1873-1887
31. Garcia-Calvo M., Lisnock J.-M., Bull H.G., Hawes B.E., Burnett D.A., Braun M.P., Crona J.H., Davis Jr. H.R., Dean D.C., and Detmers P.A. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 102 (2005) 8132-8137
32. Lowe C.V., and John C. Naturally occurring β-lactones: occurrence, syntheses and properties. A review. Org Prep Proced Int 27 (1995) 305-346
33. Hadvary P., Sidler W., Meister W., Vetter W., and Wolfer H. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J Biol Chem 266 (1991) 2021-2027
34. Asler I.L., Zehl M., Kovacic F., Mueller R., Abramic M., Allmaier G., and Kojic-Prodic B. Mass spectrometric evidence of covalently-bound tetrahydrolipstatin at the catalytic serine of Streptomyces rimosus lipase. Biochim Biophys Acta 1770 (2007) 163-170 [General Subjects]
35. Lupu R., and Menendez J.A. Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?. Curr Pharm Biotech 7 (2006) 483-494
36. Kridel S.J., Axelrod F., Rozenkrantz N., and Smith J.W. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64 (2004) 2070-2075
37. Dowling S., Cox J., and Cenedella R.J. Inhibition of fatty acid synthase by orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo. Lipids 44 (2009) 489-498
38. Pemble IV C.W., Johnson L.C., Kridel S.J., and Lowther W.T. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol 14 (2007) 704-709
39. Richardson R.D., Ma G., Oyola Y., Zancanella M.I., Knowles L.M., Cieplak P., Romo D., and Smith J.W. Synthesis of novel β-lactone inhibitors of fatty acid synthase. J Med Chem 51 (2008) 5285-5296
40. Pojer F., Ferrer J.-L., Richard S.B., Nagegowda D.A., Chye M.-L., Bach T.J., and Noel J.P. Structural basis for the design of potent and species-specific inhibitors of 3-hydroxy-3-methylglutaryl CoA synthases. Proc Natl Acad Sci U S A 103 (2006) 11491-11496
41. Omura S., Fujimoto T., Otoguro K., Matsuzaki K., Moriguchi R., Tanaka H., and Sasaki Y. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J Antibiot 44 (1991) 113-116
42. Fenteany G., Standaert R.F., Reichard G.A., Corey E.J., and Schreiber S.L. A β-Lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc Natl Acad Sci U S A 91 (1994) 3358-3362
43. Huang Z., Feng Y., Chen D., Wu X., Huang S., Wang X., Xiao X., Li W., Huang N., Gu L., et al. Structural basis for activation and inhibition of the secreted chlamydia protease CPAF. Cell Host Microbe 4 (2008) 529-542
44. Fenteany G., Standaert R.F., Lane W.S., Choi S., Corey E.J., and Schreiber S.L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268 (1995) 726-731
45. Dick L.R., Cruikshank A.A., Grenier L., Melandri F.D., Nunes S.L., and Stein R.L. Mechanistic studies on the inactivation of the proteasome by lactacystin. A central role for clasto-lactacystin β-lactone. J Biol Chem 271 (1996) 7273-7276
46. Soucy F., Grenier L., Behnke M.L., Destree A.T., McCormack T.A., Adams J., and Plamondon L. A novel and efficient synthesis of a highly active analogue of clasto-lactacystin β-lactone. J Am Chem Soc 121 (1999) 9967-9976
47. Shah I.M., Lees K.R., Pien C.P., and Elliott P.J. Early clinical experience with the novel proteasome inhibitor PS-519. Br J Clin Pharmacol 54 (2002) 269-276
48. Manam R.R., McArthur K.A., Chao T.-H., Weiss J., Ali J.A., Palombella V.J., Groll M., Lloyd G.K., Palladino M.A., Neuteboom S.T.C., et al. Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides. J Med Chem 51 (2008) 6711-6724
49. Groll M., Huber R., and Potts B.C.M. Crystal structure of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of a β-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 128 (2006) 5136-5141
50. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M., Mitsiades C., Mitsiades N., Yasui H., Letai A., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 8 (2005) 407-419